{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:09:55Z","timestamp":1761512995708,"version":"3.38.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genet Vaccines Ther"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C virus (HCV) infection is a major worldwide problem causes acute and chronic HCV infection. Current treatment of HCV includes pegylated interferon-\u03b1 (PEG IFN- \u03b1) plus ribavirin (RBV) which has significant side effects depending upon the type of genotype. Currently, there is a need to develop antiviral agents, both from synthetic chemistry and Herbal sources. In the last decade, various novel HCV replication, helicase and entry inhibitors have been synthesized and some of which have been entered in different phases of clinical trials. Successful results have been acquired by executing combinational therapy of compounds with standard regime in different HCV replicons. Even though, diverse groups of compounds have been described as antiviral targets against HCV via Specifically Targeted Antiviral Therapy for hepatitis C (STAT-C) approach (in which compounds are designed to directly block HCV or host proteins concerned in HCV replication), still there is a need to improve the properties of existing antiviral compounds. In this review, we sum up potent antiviral compounds against entry, unwinding and replication of HCV and discussed their activity in combination with standard therapy. Conclusively, further innovative research on chemical compounds will lead to consistent standard therapy with fewer side effects.<\/jats:p>","DOI":"10.1186\/1479-0556-9-11","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T18:20:01Z","timestamp":1308853201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Antiviral drugs against hepatitis C virus"],"prefix":"10.1186","volume":"9","author":[{"given":"Sidra","family":"Rehman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman A","family":"Ashfaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,23]]},"reference":[{"key":"93_CR1","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2174\/138161208784746770","volume":"14","author":"V Baldo","year":"2008","unstructured":"Baldo V, Baldovin T, Trivello R, Floreani A: Epidemiology of HCV infection. Curr Pharm Des. 2008, 14: 1646-1654. 10.2174\/138161208784746770.","journal-title":"Curr Pharm Des"},{"key":"93_CR2","first-page":"4","volume":"41","author":"NS Raja","year":"2008","unstructured":"Raja NS, Janjua NK: Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect. J Microbiol Immunol Infect. 2008, 41: 4-8.","journal-title":"J Microbiol Immunol Infect"},{"key":"93_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989, 244: 359-362. 10.1126\/science.2523562.","journal-title":"Science"},{"key":"93_CR4","first-page":"55","volume":"242","author":"KE Reed","year":"2000","unstructured":"Reed KE, Rice CM: Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol. 2000, 242: 55-84.","journal-title":"Curr Top Microbiol Immunol"},{"key":"93_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ncpgasthep1025","volume":"5","author":"M Pinzani","year":"2008","unstructured":"Pinzani M, Vizzutti F, Arena U, Marra F: Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol. 2008, 5: 95-106. 10.1038\/ncpgasthep1025.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"93_CR6","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","volume":"38","author":"SL Friedman","year":"2003","unstructured":"Friedman SL: Liver fibrosis -- from bench to bedside. J Hepatol. 2003, 38 (Suppl 1): S38-53.","journal-title":"J Hepatol"},{"key":"93_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/jhep.2003.50267","volume":"38","author":"T Poynard","year":"2003","unstructured":"Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003, 38: 75-85.","journal-title":"Hepatology"},{"key":"93_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1099\/vir.0.008300-0","volume":"90","author":"ME Burlone","year":"2009","unstructured":"Burlone ME, Budkowska A: Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol. 2009, 90: 1055-1070. 10.1099\/vir.0.008300-0.","journal-title":"J Gen Virol"},{"key":"93_CR9","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1128\/JVI.00024-06","volume":"80","author":"E Blanchard","year":"2006","unstructured":"Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouille Y: Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol. 2006, 80: 6964-6972. 10.1128\/JVI.00024-06.","journal-title":"J Virol"},{"key":"93_CR10","doi-asserted-by":"publisher","first-page":"11571","DOI":"10.1128\/JVI.01717-06","volume":"80","author":"L Meertens","year":"2006","unstructured":"Meertens L, Bertaux C, Dragic T: Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol. 2006, 80: 11571-11578. 10.1128\/JVI.01717-06.","journal-title":"J Virol"},{"key":"93_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04082","volume":"436","author":"JJ Feld","year":"2005","unstructured":"Feld JJ, Hoofnagle JH: Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005, 436: 967-972. 10.1038\/nature04082.","journal-title":"Nature"},{"key":"93_CR12","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"S Zeuzem","year":"2000","unstructured":"Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000, 343: 1666-1672. 10.1056\/NEJM200012073432301.","journal-title":"N Engl J Med"},{"key":"93_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nature04080","volume":"436","author":"R De Francesco","year":"2005","unstructured":"De Francesco R, Migliaccio G: Challenges and successes in developing new therapies for hepatitis C. Nature. 2005, 436: 953-960. 10.1038\/nature04080.","journal-title":"Nature"},{"key":"93_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1128\/AAC.01008-06","volume":"51","author":"W Hao","year":"2007","unstructured":"Hao W, Herlihy KJ, Zhang NJ, Fuhrman SA, Doan C, Patick AK, Duggal R: Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob Agents Chemother. 2007, 51: 95-102. 10.1128\/AAC.01008-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1021\/jm050855s","volume":"49","author":"R Tedesco","year":"2006","unstructured":"Tedesco R, Shaw AN, Bambal R, Chai D, Concha NO, Darcy MG, Dhanak D, Fitch DM, Gates A, Gerhardt WG: 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem. 2006, 49: 971-983. 10.1021\/jm050855s.","journal-title":"J Med Chem"},{"key":"93_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ab.2004.07.031","volume":"334","author":"P Zuck","year":"2004","unstructured":"Zuck P, Murray EM, Stec E, Grobler JA, Simon AJ, Strulovici B, Inglese J, Flores OA, Ferrer M: A cell-based beta-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. Anal Biochem. 2004, 334: 344-355. 10.1016\/j.ab.2004.07.031.","journal-title":"Anal Biochem"},{"key":"93_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.molcel.2005.04.004","volume":"18","author":"C Wang","year":"2005","unstructured":"Wang C, Gale M, Keller BC, Huang H, Brown MS, Goldstein JL, Ye J: Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell. 2005, 18: 425-434. 10.1016\/j.molcel.2005.04.004.","journal-title":"Mol Cell"},{"key":"93_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.molcel.2005.05.014","volume":"19","author":"K Watashi","year":"2005","unstructured":"Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K: Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005, 19: 111-122. 10.1016\/j.molcel.2005.05.014.","journal-title":"Mol Cell"},{"key":"93_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.virol.2003.11.023","volume":"320","author":"J Zhang","year":"2004","unstructured":"Zhang J, Yamada O, Sakamoto T, Yoshida H, Iwai T, Matsushita Y, Shimamura H, Araki H, Shimotohno K: Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology. 2004, 320: 135-143. 10.1016\/j.virol.2003.11.023.","journal-title":"Virology"},{"key":"93_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0168-1702(97)00147-0","volume":"53","author":"RH Al","year":"1998","unstructured":"Al RH, Xie Y, Wang Y, Hagedorn CH: Expression of recombinant hepatitis C virus non-structural protein 5B in Escherichia coli. Virus Res. 1998, 53: 141-149. 10.1016\/S0168-1702(97)00147-0.","journal-title":"Virus Res"},{"key":"93_CR21","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/JVI.73.2.1649-1654.1999","volume":"73","author":"E Ferrari","year":"1999","unstructured":"Ferrari E, Wright-Minogue J, Fang JW, Baroudy BM, Lau JY, Hong Z: Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol. 1999, 73: 1649-1654.","journal-title":"J Virol"},{"key":"93_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.antiviral.2008.08.004","volume":"81","author":"A Sampath","year":"2009","unstructured":"Sampath A, Padmanabhan R: Molecular targets for flavivirus drug discovery. Antiviral Res. 2009, 81: 6-15. 10.1016\/j.antiviral.2008.08.004.","journal-title":"Antiviral Res"},{"key":"93_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jhep.2005.05.013","volume":"43","author":"R Bartenschlager","year":"2005","unstructured":"Bartenschlager R: The hepatitis C virus replicon system: from basic research to clinical application. J Hepatol. 2005, 43: 210-216. 10.1016\/j.jhep.2005.05.013.","journal-title":"J Hepatol"},{"key":"93_CR24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1128\/AAC.00939-08","volume":"53","author":"L Coelmont","year":"2009","unstructured":"Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, Neyts J: Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother. 2009, 53: 967-976. 10.1128\/AAC.00939-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR25","doi-asserted-by":"crossref","unstructured":"Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G: DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 5: e13687-","DOI":"10.1371\/journal.pone.0013687"},{"key":"93_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1128\/AAC.01081-08","volume":"53","author":"M Flint","year":"2009","unstructured":"Flint M, Mullen S, Deatly AM, Chen W, Miller LZ, Ralston R, Broom C, Emini EA, Howe AY: Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother. 2009, 53: 401-411. 10.1128\/AAC.01081-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR27","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","volume":"49","author":"SW Ludmerer","year":"2005","unstructured":"Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ, LaFemina RL: Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother. 2005, 49: 2059-2069. 10.1128\/AAC.49.5.2059-2069.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.antiviral.2006.07.005","volume":"73","author":"RL Tripathi","year":"2007","unstructured":"Tripathi RL, Krishnan P, He Y, Middleton T, Pilot-Matias T, Chen CM, Lau DT, Lemon SM, Mo H, Kati W, Molla A: Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Res. 2007, 73: 40-49. 10.1016\/j.antiviral.2006.07.005.","journal-title":"Antiviral Res"},{"key":"93_CR29","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1128\/AAC.01599-08","volume":"53","author":"ST Shi","year":"2009","unstructured":"Shi ST, Herlihy KJ, Graham JP, Nonomiya J, Rahavendran SV, Skor H, Irvine R, Binford S, Tatlock J, Li H: Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother. 2009, 53: 2544-2552. 10.1128\/AAC.01599-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1021\/jm801418v","volume":"52","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Sharon A, Bal C, Wang J, Allu M, Huang Z, Murray MG, Bassit L, Schinazi RF, Korba B, Chu CK: Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. J Med Chem. 2009, 52: 206-213. 10.1021\/jm801418v.","journal-title":"J Med Chem"},{"key":"93_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/095632020801900104","volume":"19","author":"L Bassit","year":"2008","unstructured":"Bassit L, Grier J, Bennett M, Schinazi RF: Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir Chem Chemother. 2008, 19: 25-31.","journal-title":"Antivir Chem Chemother"},{"key":"93_CR32","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1128\/AAC.00078-08","volume":"52","author":"BE Korba","year":"2008","unstructured":"Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS: Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008, 52: 4069-4071. 10.1128\/AAC.00078-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR33","doi-asserted-by":"crossref","unstructured":"Einav S, Sobol HD, Gehrig E, Glenn JS: The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 202: 65-74.","DOI":"10.1086\/653080"},{"key":"93_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/hep.22987","volume":"50","author":"Z Liu","year":"2009","unstructured":"Liu Z, Robida JM, Chinnaswamy S, Yi G, Robotham JM, Nelson HB, Irsigler A, Kao CC, Tang H: Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A. Hepatology. 2009, 50: 25-33. 10.1002\/hep.22987.","journal-title":"Hepatology"},{"key":"93_CR35","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1128\/AAC.01548-07","volume":"52","author":"W Yang","year":"2008","unstructured":"Yang W, Zhao Y, Fabrycki J, Hou X, Nie X, Sanchez A, Phadke A, Deshpande M, Agarwal A, Huang M: Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother. 2008, 52: 2043-2052. 10.1128\/AAC.01548-07.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"93_CR36","first-page":"A783","volume":"46","author":"JC Pottage","year":"2007","unstructured":"Pottage JC, Lawitz E, Mazur D, Wyles H, Vargas R, Ghalib R, Gugliotti M, Donohue aHR: Short-term antiviral activity and safety of ACH-806 (GS-9132), an NS4A antagonist, in HCV genotype 1 infected individuals. J Hepatol. 2007, 46 (Suppl 1): A783-","journal-title":"J Hepatol"},{"key":"93_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1139\/o05-149","volume":"84","author":"SM Sagan","year":"2006","unstructured":"Sagan SM, Rouleau Y, Leggiadro C, Supekova L, Schultz PG, Su AI, Pezacki JP: The influence of cholesterol and lipid metabolism on host cell structure and hepatitis C virus replication. Biochem Cell Biol. 2006, 84: 67-79. 10.1139\/o05-149.","journal-title":"Biochem Cell Biol"},{"key":"93_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1472-6769-9-2","volume":"9","author":"JP Pezacki","year":"2009","unstructured":"Pezacki JP, Sagan SM, Tonary AM, Rouleau Y, Belanger S, Supekova L, Su AI: Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem Biol. 2009, 9: 2-10.1186\/1472-6769-9-2.","journal-title":"BMC Chem Biol"},{"key":"93_CR39","doi-asserted-by":"crossref","unstructured":"Cheng Y, Tsou LK, Cai J, Aya T, Dutschman GE, Gullen EA, Grill SP, Chen AP, Lindenbach BD, Hamilton AD, Cheng YC: A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro. Antimicrob Agents Chemother. 54: 197-206.","DOI":"10.1128\/AAC.01206-09"},{"key":"93_CR40","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1128\/AAC.01058-08","volume":"53","author":"TI Lin","year":"2009","unstructured":"Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, Vermeiren K, Rosenquist A, Edlund M, Samuelsson B: In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 2009, 53: 1377-1385. 10.1128\/AAC.01058-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR41","doi-asserted-by":"crossref","unstructured":"Hopkins S, Scorneaux B, Huang Z, Murray MG, Wring S, Smitley C, Harris R, Erdmann F, Fischer G, Ribeill Y: SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 54: 660-672.","DOI":"10.1128\/AAC.00660-09"},{"issue":"Suppl 1","key":"93_CR42","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/S0168-8278(09)60091-X","volume":"50","author":"S Hopkins","year":"2009","unstructured":"Hopkins S, Heuman D, Gavis E, Lalezari J, Glutzer E, DiMassimo B, Rusnak P, Wring S: Safety, plasma, pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J Hepatol. 2009, 50 (Suppl 1): S36-Smitley SaRYS, plasma, pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection","journal-title":"J Hepatol"},{"key":"93_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1128\/AAC.00834-07","volume":"52","author":"ST Shi","year":"2008","unstructured":"Shi ST, Herlihy KJ, Graham JP, Fuhrman SA, Doan C, Parge H, Hickey M, Gao J, Yu X, Chau F: In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother. 2008, 52: 675-683. 10.1128\/AAC.00834-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR44","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1128\/AAC.00699-08","volume":"52","author":"SD Seiwert","year":"2008","unstructured":"Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A: Preclinical characteristics of the hepatitis C virus NS3\/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 2008, 52: 4432-4441. 10.1128\/AAC.00699-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"93_CR45","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2008.12.028","volume":"50","author":"I Vliegen","year":"2009","unstructured":"Vliegen I, Paeshuyse J, De Burghgraeve T, Lehman LS, Paulson M, Shih IH, Mabery E, Boddeker N, De Clercq E, Reiser H: Substituted imidazopyridines as potent inhibitors of HCV replication. J Hepatol. 2009, 50: 999-1009. 10.1016\/j.jhep.2008.12.028.","journal-title":"J Hepatol"},{"key":"93_CR46","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1016\/j.bmcl.2008.02.053","volume":"18","author":"JT Randolph","year":"2008","unstructured":"Randolph JT, Zhang X, Huang PP, Klein LL, Kurtz KA, Konstantinidis AK, He W, Kati WM, Kempf DJ: Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor. Bioorg Med Chem Lett. 2008, 18: 2745-2750. 10.1016\/j.bmcl.2008.02.053.","journal-title":"Bioorg Med Chem Lett"},{"key":"93_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bmcl.2007.11.088","volume":"18","author":"TD Bosse","year":"2008","unstructured":"Bosse TD, Larson DP, Wagner R, Hutchinson DK, Rockway TW, Kati WM, Liu Y, Masse S, Middleton T, Mo H: Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors. Bioorg Med Chem Lett. 2008, 18: 568-570. 10.1016\/j.bmcl.2007.11.088.","journal-title":"Bioorg Med Chem Lett"},{"key":"93_CR48","doi-asserted-by":"crossref","unstructured":"Bogen SL, Arasappan A, Velazquez F, Blackman M, Huelgas R, Pan W, Siegel E, Nair LG, Venkatraman S, Guo Z: Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species. Bioorg Med Chem. 18: 1854-1865.","DOI":"10.1016\/j.bmc.2010.01.044"},{"key":"93_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jhep.2008.03.027","volume":"49","author":"E Lawitz","year":"2008","unstructured":"Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG: Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008, 49: 163-169. 10.1016\/j.jhep.2008.03.027.","journal-title":"J Hepatol"},{"key":"93_CR50","doi-asserted-by":"crossref","unstructured":"Shan GZ, Peng ZG, Li YH, Li D, Li YP, Meng S, Gao LY, Jiang JD, Li ZR: A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure-activity relationships and anti-HCV activity in GS4.3 replicon cells. J Antibiot (Tokyo). 64: 177-182.","DOI":"10.1038\/ja.2010.161"},{"key":"93_CR51","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0092-8674(02)00804-8","volume":"109","author":"JR Lorsch","year":"2002","unstructured":"Lorsch JR: RNA chaperones exist and DEAD box proteins get a life. Cell. 2002, 109: 797-800. 10.1016\/S0092-8674(02)00804-8.","journal-title":"Cell"},{"key":"93_CR52","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1097-2765(01)00329-X","volume":"8","author":"NK Tanner","year":"2001","unstructured":"Tanner NK, Linder P: DExD\/H box RNA helicases: from generic motors to specific dissociation functions. Mol Cell. 2001, 8: 251-262. 10.1016\/S1097-2765(01)00329-X.","journal-title":"Mol Cell"},{"key":"93_CR53","doi-asserted-by":"publisher","first-page":"R961","DOI":"10.1016\/S0960-9822(01)00574-7","volume":"11","author":"P Linder","year":"2001","unstructured":"Linder P, Stutz F: mRNA export: travelling with DEAD box proteins. Curr Biol. 2001, 11: R961-963. 10.1016\/S0960-9822(01)00574-7.","journal-title":"Curr Biol"},{"key":"93_CR54","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0968-0004(99)01376-6","volume":"24","author":"J de la Cruz","year":"1999","unstructured":"de la Cruz J, Kressler D, Linder P: Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families. Trends Biochem Sci. 1999, 24: 192-198. 10.1016\/S0968-0004(99)01376-6.","journal-title":"Trends Biochem Sci"},{"key":"93_CR55","doi-asserted-by":"crossref","unstructured":"Belon CA, High YD, Lin TI, Pauwels F, Frick DN: Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. Biochemistry. 49: 1822-1832.","DOI":"10.1021\/bi901974a"},{"key":"93_CR56","doi-asserted-by":"publisher","first-page":"8846","DOI":"10.1016\/j.bmc.2008.08.074","volume":"16","author":"A Stankiewicz-Drogon","year":"2008","unstructured":"Stankiewicz-Drogon A, Palchykovska LG, Kostina VG, Alexeeva IV, Shved AD, Boguszewska-Chachulska AM: New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection. Bioorg Med Chem. 2008, 16: 8846-8852. 10.1016\/j.bmc.2008.08.074.","journal-title":"Bioorg Med Chem"},{"key":"93_CR57","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1021\/jm8011905","volume":"52","author":"CS Chen","year":"2009","unstructured":"Chen CS, Chiou CT, Chen GS, Chen SC, Hu CY, Chi WK, Chu YD, Hwang LH, Chen PJ, Chen DS: Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase. J Med Chem. 2009, 52: 2716-2723. 10.1021\/jm8011905.","journal-title":"J Med Chem"},{"key":"93_CR58","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1046\/j.1432-1033.2003.03540.x","volume":"270","author":"P Borowski","year":"2003","unstructured":"Borowski P, Deinert J, Schalinski S, Bretner M, Ginalski K, Kulikowski T, Shugar D: Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase\/helicase activities of hepatitis C and related viruses. Eur J Biochem. 2003, 270: 1645-1653. 10.1046\/j.1432-1033.2003.03540.x.","journal-title":"Eur J Biochem"},{"key":"93_CR59","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/095632020501600504","volume":"16","author":"M Bretner","year":"2005","unstructured":"Bretner M, Baier A, Kopanska K, Najda A, Schoof A, Reinholz M, Lipniacki A, Piasek A, Kulikowski T, Borowski P: Synthesis and biological activity of 1H-benzotriazole and 1H-benzimidazole analogues--inhibitors of the NTpase\/helicase of HCV and of some related Flaviviridae. Antivir Chem Chemother. 2005, 16: 315-326.","journal-title":"Antivir Chem Chemother"},{"key":"93_CR60","doi-asserted-by":"crossref","unstructured":"Najda-Bernatowicz A, Krawczyk M, Stankiewicz-Drogon A, Bretner M, Boguszewska-Chachulska AM: Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication. Bioorg Med Chem. 18: 5129-5136.","DOI":"10.1016\/j.bmc.2010.05.066"},{"key":"93_CR61","doi-asserted-by":"publisher","first-page":"9637","DOI":"10.1021\/bi047437u","volume":"44","author":"G Maga","year":"2005","unstructured":"Maga G, Gemma S, Fattorusso C, Locatelli GA, Butini S, Persico M, Kukreja G, Romano MP, Chiasserini L, Savini L: Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry. 2005, 44: 9637-9644. 10.1021\/bi047437u.","journal-title":"Biochemistry"},{"key":"93_CR62","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1055\/s-2007-990249","volume":"73","author":"HY Lee","year":"2007","unstructured":"Lee HY, Yum JH, Rho YK, Oh SJ, Choi HS, Chang HB, Choi DH, Leem MJ, Choi EJ, Ryu JM, Hwang SB: Inhibition of HCV replicon cell growth by 2-arylbenzofuran derivatives isolated from Mori Cortex Radicis. Planta Med. 2007, 73: 1481-1485. 10.1055\/s-2007-990249.","journal-title":"Planta Med"},{"key":"93_CR63","doi-asserted-by":"crossref","unstructured":"Chockalingam K, Simeon RL, Rice CM, Chen Z: A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. Proc Natl Acad Sci USA. 107: 3764-3769.","DOI":"10.1073\/pnas.0915117107"},{"key":"93_CR64","doi-asserted-by":"crossref","unstructured":"Gastaminza P, Whitten-Bauer C, Chisari FV: Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci USA. 107: 291-296.","DOI":"10.1073\/pnas.0912966107"},{"key":"93_CR65","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1124\/mol.56.5.989","volume":"56","author":"G Cai","year":"1999","unstructured":"Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999, 56: 989-996.","journal-title":"Mol Pharmacol"},{"key":"93_CR66","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0028-3908(97)00054-3","volume":"36","author":"SC Lummis","year":"1997","unstructured":"Lummis SC, Baker J: Radioligand binding and photoaffinity labelling studies show a direct interaction of phenothiazines at 5-HT3 receptors. Neuropharmacology. 1997, 36: 665-670. 10.1016\/S0028-3908(97)00054-3.","journal-title":"Neuropharmacology"},{"key":"93_CR67","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)38891-3","volume":"295","author":"K Herrick-Davis","year":"2000","unstructured":"Herrick-Davis K, Grinde E, Teitler M: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000, 295: 226-232.","journal-title":"J Pharmacol Exp Ther"},{"key":"93_CR68","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1021\/np900549e","volume":"72","author":"H Zhang","year":"2009","unstructured":"Zhang H, Rothwangl K, Mesecar AD, Sabahi A, Rong L, Fong HH: Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. J Nat Prod. 2009, 72: 2158-2162. 10.1021\/np900549e.","journal-title":"J Nat Prod"},{"key":"93_CR69","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.chembiol.2006.08.010","volume":"13","author":"B Rakic","year":"2006","unstructured":"Rakic B, Clarke J, Tremblay TL, Taylor J, Schreiber K, Nelson KM, Abrams SR, Pezacki JP: A small-molecule probe for hepatitis C virus replication that blocks protein folding. Chem Biol. 2006, 13: 1051-1060. 10.1016\/j.chembiol.2006.08.010.","journal-title":"Chem Biol"},{"key":"93_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1074\/jbc.M703988200","volume":"283","author":"L Supekova","year":"2008","unstructured":"Supekova L, Supek F, Lee J, Chen S, Gray N, Pezacki JP, Schlapbach A, Schultz PG: Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem. 2008, 283: 29-36.","journal-title":"J Biol Chem"},{"key":"93_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.chembiol.2005.10.006","volume":"13","author":"B Rakic","year":"2006","unstructured":"Rakic B, Sagan SM, Noestheden M, Belanger S, Nan X, Evans CL, Xie XS, Pezacki JP: Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication. Chem Biol. 2006, 13: 23-30. 10.1016\/j.chembiol.2005.10.006.","journal-title":"Chem Biol"}],"container-title":["Genetic Vaccines and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-0556-9-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:50:45Z","timestamp":1741272645000},"score":1,"resource":{"primary":{"URL":"https:\/\/gvt-journal.biomedcentral.com\/articles\/10.1186\/1479-0556-9-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,23]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1186\/1479-0556-9-11","relation":{},"ISSN":["1479-0556"],"issn-type":[{"type":"electronic","value":"1479-0556"}],"subject":[],"published":{"date-parts":[[2011,6,23]]},"assertion":[{"value":"21 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"11"}}